Sustained Viral Suppression in Multidrug-Resistant HIV With Lenacapavir at 3 Years

(MedPage Today) -- In 3-year data from the CAPELLA study, the subcutaneous, long-acting capsid inhibitor lenacapavir (Sunlenca) demonstrated sustained suppression with no emergence of resistance in highly treatment-experienced individuals with...